IP Library Patent Application 12330704
Patent Application
App. No. 12/330,704

Treatment for Organ Regeneration with Combination of Drug and Biologics

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
12/330,704
Abstract

Combination therapies of drugs and biologics for treatment of acute and chronic organ degeneration are disclosed. More specifically, the use of morphogens, stem cells, and anti-inflammatories or inhibitors for the renin-angiotensin-aldosterone system (RAAS) for the treatment of acute and chronic renal disease is disclosed.

Claims (14)

1 . A method of treating conditions which place mammals at a risk of acute or chronic renal failure, the method comprising administering a combination of at least one morphogen, stem cells and an anti-inflammatory or an inhibitor of the renin-angiotensin-aldosterone system.

2 . The method of claim 1 wherein said morphogen is rhGDF-5.

3 . The method of claim 2 wherein said rhGDF-5 is administered intravenously, intraperitoneal or by renal artery or subcapsular injection, or locally by implantation in matrices.

4 . The method of claim 1 wherein said stem cells are bone marrow mesenchymal.

5 . The method of claim 1 wherein said stem cells are adult stem cells from any tissue.

6 . The method of claim 1 wherein said stem cells are from any developmental stage.

7 . The method of claim 1 wherein said stem cells are renal cells induced with morphogens.

8 . The method of claim 1 wherein said inhibitors of RAAS is ACE inhibitors,

9 . The method of claim 1 wherein said inhibitors of RAAS is rennin inhibitors.

10 . The method of claim 1 wherein said inhibitors of RAAS is aldosterone receptor antagonists.

11 . The method of claim 1 wherein said anti-inflammatories are from the 38 MAP kinase inhibitors.

12 . The method of claim 1 wherein said anti-inflammatories are antibodies against pro-inflammatory cytokines.

13 . The method of claim 1 wherein said anti-inflammatories are antibodies against chemoattractant molecules.

14 . The method of claim 1 wherein said anti-inflammatories are cell cycle inhibitors.

Assignments (6)
MERGER Recorded May 7, 2013
From: ADVANCED TECHNOLOGIES AND REGENERATIVE MEDICINE, LLC
To: DEPUY ORTHOPAEDICS, INC.
Reel/Frame 030360/0114 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 7, 2013
From: DEPUY ORTHOPAEDICS, INC.
To: DEPUY SPINE, INC.
Reel/Frame 030360/0164 →
CHANGE OF NAME Recorded May 7, 2013
From: DEPUY SPINE, INC.
To: DEPUY SPINE, LLC
Reel/Frame 030360/0171 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 7, 2013
From: DEPUY SPINE, LLC
To: HAND INNOVATIONS LLC
Reel/Frame 030360/0250 →
CHANGE OF NAME Recorded May 7, 2013
From: HAND INNOVATIONS LLC
To: DEPUY SYNTHES PRODUCTS, LLC
Reel/Frame 030360/0260 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 9, 2008
From: FANG, CARRIE H.; DHANARAJ, SRIDEVI; GEESIN, JEFFREY C.
To: ADVANCED TECHNOLOGIES AND REGENERATIVE MEDICINE, LLC
Reel/Frame 021947/0493 →